



MITHRA SIGNS AN LOI FOR THE JAPANESE AND ASEAN RIGHTS ON ESTETROL IN WOMEN'S HEALTH WITH THE MARKET LEADER IN JAPAN, FUJI PHARMACEUTICALS

- **LoI between Mithra and Fuji, market leader in Japan, for Estetrol-based products in Women's Health; multiple indications to be determined in common agreement**
- **Japanese clinical trials to be conducted and financed by Fuji**
- **Potential milestones in the double-digit million EUR range**

Liège, Belgium 24 June 2016 – Mithra Pharmaceuticals is pleased to announce it has signed a Letter of Intent with Fuji Pharmaceuticals to work towards a broad partnership on Estetrol in women's health, in multiple indications to be determined in common agreement. Both parties intend to finalize their partnership in an agreement before the end of this year. This important partnership (involving investments and potential milestones in the double-digit million range) between Mithra and Fuji Pharmaceuticals, the market leader in Women's Health in Japan, validates Mithra's strategy of seeking out the Women's Health leaders in markets around the world.

The plan is that even as the phase III on Estetrol in the US and the EU is ongoing, Fuji Pharmaceuticals will conduct its own clinical trials in Japan, a specific requirement from the Japanese authorities for all new products to be introduced in Japan. Depending on the indication and the region, in Mithra's experience, clinical trials can have a cost of several tens of millions of euros. The fact that Fuji Pharma would be willing to make the considerable investment involved in conducting these trials offers a potent confirmation of the potential of Estetrol-based products.

The importance of this potential partnership for Mithra is further underlined by the indicative financial terms being discussed, which offer the potential for milestones in the double-digit million euro range.

In addition, the Japanese women's health market is an interesting market with a huge upside potential, and Mithra is confident Fuji, as the market leader, could be the ideal partner to help Mithra's Estetrol-based products address and develop this market. In addition, the partnership is aimed to cover the countries of the ASEAN (Association of Southeast Asian Nations).

François Fornieri, CEO Mithra Pharmaceuticals : *"This LoI clearly demonstrates our desire to partner-up outside the US and EU with market leaders in women's health. Fuji Pharmaceuticals is for Mithra an extremely attractive partner in that region given their market leader position. Their willingness to invest substantially into this partnership strengthens our belief in the strength of the case for products based Estetrol. Today in Japan still too many women fear hormone treatments and Fuji has been looking for safe, natural based hormones, which they found in Estetrol."*

Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22

investorrelations@mithra.com

About Fuji Pharma :

Fuji Pharma is a pharmaceutical company established in 1965, based in Japan and focused on the development, manufacture, and marketing of pharmaceutical products, such as injection agents, internal drugs, drugs for external use, and diagnostic products. Fuji is active in the fields of medical care for women (where it is leader in the Japanese market), in vitro diagnostics, acute medical care products and curative medicine (injection agents), as well as information regarding pharmaceuticals and health. Fuji Pharma is listed on the Tokyo Stock exchange, with a market cap of around 35 billion Yen and annual revenues in 2015 in excess of 31 billion Yen. For more information please visit the site www.fujipharma.jp/english/ir/

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com